Risk of lung cancer in Parkinson's disease

Oncotarget

Volumn 7, Issue 47, 2016, Pages 77319-77325

  Xie, Xin ^a   Luo, Xiaoguang ^a   Xie, Mingliang ^b   Liu, Yang ^a   Wu, Ting ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Department of Military Psychology   (China)

Author keywords

Lung neoplasms; Meta analysis; Parkinson's disease; Risk

Indexed keywords

ARTICLE; ASIAN; CANCER RISK; DISEASE ASSOCIATION; GENDER; HUMAN; LUNG CANCER; MEDICAL LITERATURE; PARKINSON DISEASE; SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; WESTERN HEMISPHERE; CANADA; FEMALE; ISRAEL; JAPAN; LUNG TUMOR; MALE; META ANALYSIS; ODDS RATIO; SWEDEN; TAIWAN; UNITED KINGDOM; UNITED STATES;

CANADA; FEMALE; HUMANS; ISRAEL; JAPAN; LUNG NEOPLASMS; MALE; ODDS RATIO; PARKINSON DISEASE; SWEDEN; TAIWAN; UNITED KINGDOM; UNITED STATES;

EID: 84998692917     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12964     Document Type: Article

References (38)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5:525-535.
2. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010; 21:697-707.
3. Catala-Lopez F, Suarez-Pinilla M, Suarez-Pinilla P, Valderas JM, Gomez-Beneyto M, Martinez S, Balanza-Martinez V, Climent J, Valencia A, McGrath J, Crespo-Facorro B, Sanchez-Moreno J, Vieta E, et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577, 013 participants of 50 observational studies. Psychother Psychosom. 2014; 83:89-105.
4. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011; 76:2002-2009.
5. Ong EL, Goldacre R, Goldacre M. Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. Eur J Cancer. 2014; 50:2456-2462.
6. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev. 2007; 16:1260-1265.
7. Lin PY, Chang SN, Hsiao TH, Huang BT, Lin CH, Yang PC. Association Between Parkinson Disease and Risk of Cancer in Taiwan. JAMA Oncol. 2015; 1:633-640.
8. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010; 42:77-82.
9. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Jr., Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord. 2006; 12:185-189.
10. Copas JB, Shi JQ. Reanalysis of epidemiological evidence on lung cancer and passive smoking. BMJ. 2000; 320:417-418.
11. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol. 2000; 247:429-434.
12. Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA. Nonfatal cancer preceding Parkinson's disease: a casecontrol study. Epidemiology. 2002; 13:157-164.
13. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord. 2004; 19:49-53.
14. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord. 2010; 16:186-190.
15. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2010; 81:215-221.
16. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM. Comorbid cancer in Parkinson's disease. Mov Disord. 2010; 25:1809-1817.
17. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol. 2012; 69:1572-1577.
18. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer. 2012; 131:1904-1911.
19. Wirdefeldt K, Weibull CE, Chen H, Kamel F, Lundholm C, Fang F, Ye W. Parkinson's disease and cancer: A registerbased family study. Am J Epidemiol. 2014; 179:85-94.
20. Freedman DM, Wu J, Chen H, Engels EA, Enewold LR, Freedman ND, Goedert JJ, Kuncl RW, Gail MH, Pfeiffer RM. Associations between cancer and Parkinson's disease in U.S. elderly adults. Int J Epidemiol. 2016; [Epub ahead of print].
21. Peretz C, Gurel R, Rozani V, Gurevich T, El-Ad B, Tsamir J, Giladi N. Cancer incidence among Parkinson's disease patients in a 10-yrs time-window around disease onset: A large-scale cohort study. Parkinsonism Relat Disord. 2016; 28:68-72.
22. Tacik P, Curry S, Fujioka S, Strongosky A, Uitti RJ, van Gerpen JA, Diehl NN, Heckman MG, Wszolek ZK. Cancer in Parkinson's disease. Parkinsonism Relat Disord. 2016; [Epub ahead of print].
23. Sarkar C, Chakroborty D, Dasgupta PS, Basu S. Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. Int J Cancer. 2015; 137:744-749.
24. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord. 2012; 27:947-957.
25. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.
26. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21:2237-2246.
27. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T, Brice A, van Bergen En Henegouwen PM, Fon EA. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PIK-Akt signalling. Nat Cell Biol. 2006; 8:834-842.
28. Xiong D, Wang Y, Kupert E, Simpson C, Pinney SM, Gaba CR, Mandal D, Schwartz AG, Yang P, de Andrade M, Pikielny C, Byun J, Li Y, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet. 2015; 96:301-308.
29. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998; 352:1344-1346.
30. Wesseling C, Antich D, Hogstedt C, Rodriguez AC, Ahlbom A. Geographical differences of cancer incidence in Costa Rica in relation to environmental and occupational pesticide exposure. Int J Epidemiol. 1999; 28:365-374.
31. Frigerio R, Sanft KR, Grossardt BR, Peterson BJ, Elbaz A, Bower JH, Ahlskog JE, de Andrade M, Maraganore DM, Rocca WA. Chemical exposures and Parkinson's disease: a population-based case-control study. Mov Disord. 2006; 21:1688-1692.
32. Barnhill LM, Bronstein JM. Pesticides and Parkinson's disease: is it in your genes? Neurodegener Dis Manag. 2014; 4:197-200.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009; 339:b2535.
34. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603-605.
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-560.
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-634.
37. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101.
38. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol. 1995; 48:45-57; discussion 59-60.